Stephen Davis
Directeur Général chez ACADIA PHARMACEUTICALS INC.
Fortune : 3 M $ au 31/05/2024
Profil
M. Stephen R. Davis, CPA, est un administrateur indépendant de Heron Therapeutics, Inc. et de Bellicum Pharmaceuticals, Inc. et un directeur général et administrateur d'ACADIA Pharmaceuticals, Inc. Il est membre du conseil d'administration de Heron Therapeutics, Inc. et de Bellicum Pharmaceuticals, Inc. et d'ACADIA Pharmaceuticals, Inc. M. Davis a été précédemment employé en tant que directeur indépendant par Furiex Pharmaceuticals, Inc. et par Synageva BioPharma Corp. en tant que directeur de l'exploitation et vice-président exécutif par Ardea Biosciences, Inc. en tant que directeur exécutif par Trimeris, Inc. en tant que président, PDG, directeur financier, directeur de l'exploitation et secrétaire par Neurogen Corp. et en tant qu'avocat spécialisé dans les sociétés et les valeurs mobilières par Milbank, Tweed, Hadley & McCloy LLP. Il a obtenu son diplôme de premier cycle à la Southern Nazarene University et un diplôme de deuxième cycle à la Vanderbilt Law School.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 02/05/2024 | 155 231 ( 0,09% ) | 2 M $ | 31/05/2024 | |
HERON THERAPEUTICS INC
0,03% | 16/12/2022 | 52 032 ( 0,03% ) | 192 518 $ | 31/05/2024 |
Postes actifs de Stephen Davis
| Sociétés | Poste | Début |
|---|---|---|
| ACADIA PHARMACEUTICALS INC. | Directeur Général | 11/03/2015 |
Anciens postes connus de Stephen Davis
| Sociétés | Poste | Fin |
|---|---|---|
| BELLICUM PHARMACEUTICALS, INC. | Directeur/Membre du Conseil | 23/02/2024 |
| HERON THERAPEUTICS, INC. | Directeur/Membre du Conseil | 21/02/2023 |
| SYNAGEVA BIOPHARMA CORP | Directeur/Membre du Conseil | 22/06/2015 |
| HERON THERAPEUTICS, INC. | Directeur des opérations | 01/06/2015 |
| FURIEX PHARMACEUTICALS INC | Directeur/Membre du Conseil | 02/07/2014 |
Formation de Stephen Davis
| Southern Nazarene University | Undergraduate Degree |
| Vanderbilt Law School | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| ACADIA PHARMACEUTICALS INC. | Health Technology |
| HERON THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 7 |
|---|---|
Neurogen Corp.
 Neurogen Corp. Pharmaceuticals: MajorHealth Technology Neurogen Corp. operated as a drug discovery and development company. The company was headquartered in Branford, CT. | Health Technology |
Trimeris, Inc.
 Trimeris, Inc. Pharmaceuticals: MajorHealth Technology Trimeris, Inc. develops therapeutics for viral diseases. It is a biopharmaceutical company engaged in the discovery, development and commercialization of novel therapeutic agents for the treatment of viral disease. The core technology platform of fusion inhibition is based on blocking viral entry into host cells. The company was founded in 1993 and is headquartered in Durham, NC. | Health Technology |
Milbank LLP
 Milbank LLP Miscellaneous Commercial ServicesCommercial Services Milbank LLP provides legal services. It serves corporate, finance, financial restructuring, litigation and arbitration, securities, capital markets, trusts, estates, and exempt organizations, and tax markets. The company was founded in 1866 and is headquartered in New York, NY. | Commercial Services |
Ardea Biosciences, Inc.
 Ardea Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Ardea Biosciences, Inc. is a biotechnology company which is focused on the development of small-molecule therapeutics for the treatment of serious diseases. The company was founded in January 1994 and is headquartered in Wilmington, DE. | Health Technology |
Synageva BioPharma Corp.
 Synageva BioPharma Corp. BiotechnologyHealth Technology Synageva BioPharma Corp. is a biopharmaceutical company which focuses on the discovery, development, and commercialization of therapeutic products for patients with life-threatening rare diseases and high unmet medical need. The company is currently evaluating sebelipase alfa in global clinical trials for LAL Deficiency, a lysosomal storage disease associated with liver damage and accelerated atherosclerosis in children and adults, and in infants, premature death often before six months of age. Synageva BioPharma was founded in 1993 and is headquartered in Lexington, MA. | Health Technology |
Furiex Pharmaceuticals, Inc.
 Furiex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Furiex Pharmaceuticals, Inc. operates as a drug development collaboration company that uses innovative clinical development design to accelerate and increase value of drug development programs by advancing them through the drug discovery and development process in a cost-efficient manner. Its drug development programs are designed and driven by a core team with extensive drug development experience. Furiex Pharmaceuticals was founded in 1998 and is headquartered in Morrisville, NC. | Health Technology |
Bellicum Pharmaceuticals, Inc.
 Bellicum Pharmaceuticals, Inc. BiotechnologyHealth Technology Bellicum Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It focuses on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders. The firm uses its proprietary chemical induction of dimerization that controls components of the immune system in real time. Its product candidates include BPX-601, BPX-603, and Rivo-cel (rivogenlecleucel, formerly known as BPX-501). The company was founded by Kevin M. Slawin and David M. Spencer on July 14, 2004 and is headquartered in Houston, TX. | Health Technology |
